Price$0.10+0.00 (+4.53%)
02:15 PM07:45 PM
News · 26 weeks36+200%
2026-04-192026-10-11
Mix2290d
- SEC Filings8(36%)
- Insider7(32%)
- Other6(27%)
- Leadership1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Adagio Medical Holdings Inc4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- SECSEC Form DEF 14A filed by Adagio Medical Holdings IncDEF 14A - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECSEC Form 8-K filed by Adagio Medical Holdings Inc8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECSEC Form PRE 14A filed by Adagio Medical Holdings IncPRE 14A - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- PRAdagio Medical Announces Strategic Review Process to Maximize Shareholder ValueCompany Continues to Advance PMA Application for vCLAS Ventricular Ablation System While Board Evaluates Full Range of Strategic Options Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Board of Directors has completed a comprehensive review of the Company's business, programs, resources and capabilities and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value. In connection with this decision, the Company is implementing a reduction in workforce to align its cost structure with its prioritized
- PRAdagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center PhoenixEnrollment Underway Across Multiple Sites as Study Advances Faster, Improved ULTA Catheter for the Broadest Population of VT Patients Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company’s study evaluating its next-generation vCLAS™ Ultra Ultra-Low Temperature Ablation ("ULTA") Ventricular Ablation System. The study is designed to support a Premarket Approval ("PMA") supplement to the Company’s PMA for its first generation vCLAS system, which is presently under review by the to the U.S. Food and Drug A
- PRTeleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of DirectorsTeleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE:MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion for which Mr. Salmon was instrumental in developing the growth strategy. He previously held leadership roles across Medtronic’s Diabetes, Coronary a
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings IncSCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
- SECSEC Form 8-K filed by Adagio Medical Holdings Inc8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- INSIDERSEC Form 4 filed by Director Salmon Sean4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Mirsaeedi-Farahani Keyvan4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Cox James L4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Gardiner Sandra A.4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Mishan Orly4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Moran Timothy P.4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- SECSEC Form 10-Q filed by Adagio Medical Holdings Inc10-Q - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- PRAdagio Medical Reports Second Quarter 2026 ResultsAdagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ Ultra Ultra-Low temperature ablation catheter ("ULTA"), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration ("FDA") Anno
- PRAdagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA SystemvCLAS Ultra System Designed to Optimize Usability and Workstream to Address Entire Spectrum of Ventricular Tachycardia PatientsAdagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation ("ULTA") system under Expanded Access authorization from the U.S. Food and Drug Administration ("FDA").The patient, who presented with non-ischemic cardiomyopathy and a recent history of failed radiofrequency ("RF") and coronary venous alcohol ablations to address the ventr
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings IncSCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Adagio Medical Holdings Inc10-K/A - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
ADGM FAQ
5 questionsWhere does ADGM stock trade?
Adagio Medical Holdings Inc (ADGM) is listed on NASDAQ.What sector and industry is ADGM in?
Adagio Medical Holdings Inc operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about ADGM?
Adagio Medical Holdings Inc has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $300.00 price target on 2026-04-14. Recent price targets range from $300.00 to $400.00.What companies are similar to ADGM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ADGM side-by-side with any of them on Quantisnow.How can I track ADGM on Quantisnow?
Quantisnow aggregates Adagio Medical Holdings Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADGM to receive live email and push alerts on every new disclosure.